• Waiv, a Paris-based startup, spins out of Owkin to accelerate AI-enabled precision oncology testing.
• Formerly known as “Owkin Dx” Waiv leverages AI-driven diagnostics for better clinical decision-making and improved patient outcomes.
• Led by OTB Ventures and Alpha Intelligence Capital, the financing will be used to expand Waiv’s clinical testing solutions, strengthen pharma R&D integrations, and fuel commercial expansion.

‍

PARIS, 12 March 2026 - Waiv, a Paris-based company catalyzing AI precision testing, today announced a $33 million financing round to accelerate the global deployment of its AI precision testing platform. The financing marks Waiv’s spin out from Owkin, where its experienced team previously operated as Owkin Dx. The raise is co-led by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista and SistaFund. 

Oncology has entered an era of unprecedented biological complexity. Treatment decisions are no longer defined by single biomarkers or linear pathways, but by multidimensional signals embedded across biology, data, and care delivery. As the next wave of precision cancer therapies emerges, the demand for deeper, faster, and more scalable insights is outpacing the capabilities of traditional diagnostics.

Waiv is building the diagnostic infrastructure for this next era of precision oncology. By turning routinely generated digital histopathology and multimodal clinical data into clinically validated, AI-native precision tests, Waiv reveals actionable biology hidden in plain sight, accelerating therapeutic impact, and transforming cancer care worldwide.

Already deployed in clinical settings through its products such as RlapsRisk BC, MSIntuit Suite, and BRCAura, Waiv supports laboratories, clinicians, and drug developers with biomarker discovery, detection, and treatment-response insights in minutes, improving patient testing and stratification accuracy, streamlining diagnostic workflows, and expanding access to precision medicine for patients using data generated in routine care.

As an independent company with roots in more than a decade of medical AI research, Waiv advances a dedicated precision testing strategy. It combines large-scale multimodal data, proprietary AI, and industry expertise and is underpinned by: 

• An extensive data network and the PortrAIt consortium, one of Europe’s most comprehensive multi-institutional initiatives advancing precision medicine by providing high-quality, diverse datasets that reinforce model performance and accelerate clinical translation.
• An end-to-end AI platform, combining Waiv’s proprietary foundational models, multimodal analytics, and clinical validation within a single stack that is purpose-built to deliver clinical-grade precision tests that are generalizable across labs and regions.
• Destra, an interoperable digital pathology platform within Waiv’s tech stack that enables pathologists and labs to access and run Waiv’s full suite of tests within the workflows they already use.
• Leading pharma partnerships, establishing co-development programs with global life science leaders to advance biomarker discovery, trial enrichment, and AI-guided precision testing, including:
  
  • an AI gBRCA pre-screen test for breast cancer from H&E slides (BRCAura);
  • a collaboration with MSD for the AI-based identification of an MSI-enriched population.  

“Precision medicine only works when patients can be reliably matched to the therapies most likely to benefit them”, said Meriem Sefta, CEO and Co-Founder, Waiv. “This remains very complex to achieve. Waiv brings the scalability and speed of AI to oncology testing, while enabling drug developers to access insights that were previously out of reach. Our goal is to make accurate AI-enabled precision testing the global standard.”

Karol Szubstarski, Partner at OTB Ventures commented, “Waiv is bringing a level of technological advancement and maturity that oncology has been waiting for. Their AI tech stack, built on advanced foundation models, can convert routine pathology slides into high-resolution maps of disease biology, providing both generalizability and scalability across different clinical settings. We are excited to partner with a world-class team and support Waiv as they set a new standard for how oncology is understood and treated.”

Arnaud Barthélémy, Partner at AIC added: "What sets Waiv apart is not just its technology, but its proven clinical impact across applications from outcome prediction to biomarker detection. With exceptional scientific depth, a track record of real-world impact, and strong revenue-generating partnerships with global pharma, Waiv exemplifies how AI is set to revolutionize healthcare - driving highly personalized, efficient, and outcome-focused medicine. As a leader in AI investment since 2018, AIC is committed to supporting this essential movement for the benefit of patients."

Fabrice André, MD, PhD, Director of Research, Gustave Roussy, said: “We’ve collaborated closely with the team behind Waiv for years, and with their launch, co-developed tools like RlapsRisk BC for breast cancer can now reach a wider clinical audience, which will be a major win for patients. Built with Gustave Roussy and the PortrAIt Consortium, these solutions pave the way for  more precise patient stratification, a reduction of unnecessary procedures, and expanded access to therapies most likely to benefit each individual.”

Waiv will use the funding to expand its portfolio of clinical-grade multimodal tests, deepen its pharmaceutical integrations across R&D pipelines, and broaden international market access, enabling more laboratories and healthcare providers to adopt its precision-testing solutions.

‍

‍

###

About Waiv:

Waiv exists to catalyze precision medicine with clinical-grade, AI-powered tests that accelerate biomarker detection, outcome prediction, and treatment-response assessment across oncology. Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support treatment decisions. Waiv collaborates with global pharmaceutical companies, research institutions, diagnostic organizations and healthcare systems to bring scalable precision medicine to patients worldwide. For more information, please visit www.wearewaiv.com

‍